Flossbach Von Storch SE Cuts Stake in BioNTech SE Sponsored ADR $BNTX

Flossbach Von Storch SE lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 0.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,230,098 shares of the company’s stock after selling 29,533 shares during the quarter. BioNTech accounts for 1.8% of Flossbach Von Storch SE’s investment portfolio, making the stock its 21st biggest position. Flossbach Von Storch SE’s holdings in BioNTech were worth $450,379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the stock. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the 1st quarter valued at about $36,000. LRI Investments LLC grew its position in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares during the period. Banque Transatlantique SA acquired a new position in shares of BioNTech during the first quarter worth $80,000. Finally, Costello Asset Management INC purchased a new position in shares of BioNTech in the first quarter valued at $91,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of several analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $134.00 price target on shares of BioNTech in a research note on Monday, November 3rd. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an “overweight” rating in a research report on Tuesday, August 5th. Bank of America cut their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Finally, JPMorgan Chase & Co. cut their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $133.82.

BioNTech Stock Down 0.2%

NASDAQ:BNTX opened at $103.14 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The company has a market capitalization of $23.23 billion, a price-to-earnings ratio of -64.46 and a beta of 1.54. BioNTech SE Sponsored ADR has a one year low of $81.20 and a one year high of $129.27. The stock has a 50-day simple moving average of $102.60 and a 200 day simple moving average of $105.04.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.